236 related articles for article (PubMed ID: 29678530)
1. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
3. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.
Ahmed KA; Stallworth DG; Kim Y; Johnstone PA; Harrison LB; Caudell JJ; Yu HH; Etame AB; Weber JS; Gibney GT
Ann Oncol; 2016 Mar; 27(3):434-41. PubMed ID: 26712903
[TBL] [Abstract][Full Text] [Related]
5. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
6. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
Ahmed KA; Kim S; Arrington J; Naghavi AO; Dilling TJ; Creelan BC; Antonia SJ; Caudell JJ; Harrison LB; Sahebjam S; Gray JE; Etame AB; Johnstone PA; Yu M; Perez BA
J Neurooncol; 2017 Jun; 133(2):331-338. PubMed ID: 28466250
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.
Hall MD; McGee JL; McGee MC; Hall KA; Neils DM; Klopfenstein JD; Elwood PW
J Neurosurg; 2014 Dec; 121 Suppl():84-90. PubMed ID: 25434941
[TBL] [Abstract][Full Text] [Related]
9. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
10. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.
Ahmed KA; Freilich JM; Sloot S; Figura N; Gibney GT; Weber JS; Sarangkasiri S; Chinnaiyan P; Forsyth PA; Etame AB; Rao NG
J Neurooncol; 2015 Mar; 122(1):121-6. PubMed ID: 25519302
[TBL] [Abstract][Full Text] [Related]
11. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of reirradiation of brain metastases from small cell lung cancer with Cyberknife stereotactic radiosurgery.
Olson AC; Wegner RE; Rwigema JC; Heron DE; Burton SA; Mintz AH
J Cancer Res Ther; 2012; 8(3):411-6. PubMed ID: 23174724
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiosurgery for intraventricular brain metastases.
Farnia B; Voong KR; Brown PD; Allen PK; Guha-Thakurta N; Prabhu SS; Rao G; Wang Q; Zhao Z; Mahajan A
J Neurosurg; 2014 Dec; 121 Suppl():26-34. PubMed ID: 25434934
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer.
Minniti G; Salvati M; Muni R; Lanzetta G; Osti MF; Clarke E; Costa A; Bozzao A; Trasimeni G; Enrici RM
Anticancer Res; 2010 Jul; 30(7):3055-61. PubMed ID: 20683055
[TBL] [Abstract][Full Text] [Related]
15. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
16. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.
Yusuf MB; Amsbaugh MJ; Burton E; Chesney J; Woo S
World Neurosurg; 2017 Apr; 100():632-640.e4. PubMed ID: 28179176
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Choi CYH; Wakelee HA; Neal JW; Pinder-Schenck MC; Yu HM; Chang SD; Adler JR; Modlin LA; Harsh GR; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):16-21. PubMed ID: 28816142
[TBL] [Abstract][Full Text] [Related]
18. Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer.
Bowden G; Kano H; Caparosa E; Park SH; Niranjan A; Flickinger J; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):766-72. PubMed ID: 25658792
[TBL] [Abstract][Full Text] [Related]
19. Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis.
Patel KR; Burri SH; Boselli D; Symanowski JT; Asher AL; Sumrall A; Fraser RW; Press RH; Zhong J; Cassidy RJ; Olson JJ; Curran WJ; Shu HG; Crocker IR; Prabhu RS
J Neurooncol; 2017 Feb; 131(3):611-618. PubMed ID: 28000105
[TBL] [Abstract][Full Text] [Related]
20. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
